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Glucocorticoids (GCs) have been used successfully for over 60 years in hematologic and
non-hematologic disorders. They were first used in the treatment of a patient with adrenal
insufficiency so were administered every 6 to 8 hours to substitute for its deficiency. From
this start, GCs were given in divided dose without considering that with the exception of
surrenal insufficiency, substitution was not necessary. Actually, the pharmacologic effects
of GCs do not require substitution therapy. Different from conventional GC (2 mg/kg in
divided doses), in pulse methylprednisolone (MP), 1000 mg MP is infused within 4 hours
intravenously (iv). Bacigalupo and colleagues successfully used for the first time 30 mg/kg
MP, as pulse MP in 4 hours infusion (iv), for the treatment of acquired aplastic anemia
cases (1).
We also started to use 30-100 mg/kg MP treatment in acquired aplastic anemia cases,
and the dose was given 10-15 minutes iv before 9 a.m. with excellent response (2).
Thereafter, this megadose (MD) MP administration was applied in different hematologic
and non-hematologic disorders (3).
Following aplastic anemia, MDMP was also used in the treatment of steroid refractory
or resistant Diamond-Blackfan anemia patients, which has hereditary background, with
extraordinary response (4,5). This was verified by Dr. George Buchanon et al., president
of the American Pediatric Hematology Society (5,6).
The results of MDMP treatment in acute and chronic idiopathic thrombocytopenic
purpura (ITP) cases were somewhat surprising. Conventional corticosteroid (2 mg/kg)
seemed to delay the platelet response compared to the untreated group. Anti-platelet
antibodies decreased much faster with MDMP treatment and resulted in much earlier
platelet response (7-10).
Remission induction with MDMP in different types of leukemia was also shown to be
much faster (11-14), as in autoimmune hemolytic anemias, myelofibrosis, hemangiomas
and other hematologic disorders (3,15-17).
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MDMP response was also found to be quicker in several non-hematological diseases
(18), such as rheumatoid arthritis, acute rheumatic fever, juvenile rheumatoid arthritis,
systemic lupus erythematosus, polyarteritis nodosa, nephrotic syndrome and other diseases
with immunologic base such as alopecia totalis. Therefore, we believe whenever
corticosteroid treatment is indicated, MDMP should be used, given once a day around 5-6
a.m., except in adrenal insufficiency.
Although MDMP administration is a kind of corticosteroid treatment, it is different
from pulse methylprednisolone in which 1000 mg MP is administered iv within 4 hours,
anytime of the day, and from conventional prednisone, which is given 2 mg/kg/day, in
divided doses. MDMP treatment starts with daily 30-100 mg/kg MP dose for 3 days given
around 6 a.m. when corticosteroid level is physiologically the highest and ACTH the lowest.
It was given initially iv within 10-15 minutes and recently orally by us at once (19). Daily
MP dose was halved gradually 20-50 mg/kg for 4 days and then 10-30, 5-20, 2-10, and
1-5 mg/kg, with each dose continuing for a week. Oral MDMP was found as effective as iv
administration. A daily dose of MP is placed in a tablespoon covered by honey (since MP is
extremely bitter), and given at once, and a glass of milk is given thereafter. This early
administration of MP is less disturbing to ACTH-corticosteroid homeostasis, which is
important for steroid side effect, mostly related to suppression of ACTH secretion.
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During MDMP administration, adrenal suppression is
not expected (20); therefore, it could be discontinued
anytime, without gradually decreasing corticosteroid doses.
In MDMP administration, strict salt restriction is also not
necessary. With these explanations, MDMP could be used
whenever corticosteroid treatment is required, with the
exception of adrenal insufficiency.
With the exception of mild Cushingoid appearance,
other side effects of corticosteroids, such as hyperglycemia,
hypertension, and sodium retention, etc. are rarely
observed.
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In patients who receive MDMP, extra salt should be
omitted and they should ingest more foods containing
potassium, such as orange, carrots, and banana. With the
exception of extra calories and salt, they can consume
normal diets.
We advise that patients on MDMP treatment should
apply saline nasal washing as previously described by us for
the prevention of upper respiratory infections (21,22).
They should also walk as fast as possible to prevent muscle
atrophy.
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